Logo of Redica Systems

Redica Systems

category

Warning Letters Week of 4/20/2020: Untitled Letter to Stem Cell Firm

April 27, 2020
category

Part 2: Analysis of FDA FY2019 Drug GMP Warning Letters

April 23, 2020
category

Human Cell and Tissue Therapy Enforcement Actions Target Unapproved New Products Making Unsubstantiated Claims

April 23, 2020
category

Warning Letters Week of 4/13/2020: Compounding Pharmacy

April 21, 2020
category

Deploying Risk-Based Thinking within Management Systems

April 16, 2020
category

FDA Warning Letters Week of 4/6/2020: Devices, BIMO

April 14, 2020
category

March 483s: Most Popular and Newsworthy

April 9, 2020
category

Did COVID-19 Kill Just-in-Time Pharma Supply Chains?

April 9, 2020
category

FDA Warning Letters Week of 3/30/2020: Pharma, Device, GLP, and Compounding Pharmacy

April 7, 2020
category

CDRH Reorganization Takes a Total Product Lifecycle Approach; MDSAP, ISO Adoption, and Collaboration with MDIC Moving Forward

April 2, 2020
category

FDA Warning Letters Week of 3/22/2020: OTC and HCT/P

March 31, 2020
category

EMA Announcements Regarding Nitrosamine and MDRs

March 27, 2020
category

Big Pharma Puts Patients First in Response to COVID-19 Challenges; Collaboration with Regulators is Essential Going Forward

March 23, 2020
category

FDA Warning Letters Week of 3/8/2020: BIMO and OTC Products

March 17, 2020
category

COVID-19 Briefing: Covington & Burling Teleconference

March 17, 2020
category

Update: What are Pharma and Med Device Firms Doing About COVID-19?

March 11, 2020
category

Warning Letters Week of 3/1/2020: Device Design Controls

March 10, 2020
category

FDA Warning Letters Week of 2/23/2020: After 3-Week Absence, 8 to Drug and Device Firms

March 3, 2020